Accreditation
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists engaged in the care of patients with cancer.
Learning Objectives
- Discuss the results of recent clinical trials that are examining current and emerging treatment strategies for patients with solid tumors, including thoracic, breast, head and neck, gynecologic, CNS, gastrointestinal, and genitourinary cancers
- Evaluate recent data of currently approved and emerging therapies aimed at improving the outcomes for patients with hematologic malignancies, including patients with Hodgkin and non-Hodgkin lymphoma, chronic and acute leukemia, and multiple myeloma
- Develop strategies for integrating novel agents into the treatment armamentarium to maximize the outcomes of patients with hematologic and solid tumor malignancies
- Assess approaches that will lead to increased patient and clinician participation in clinical trials in order to address current unmet needs faced by patients with cancer
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through Partner’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving Partners permission to use this information/data to report your participation to these Boards JA-PARS.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
|
Faculty
|
Conflicts of Interest
|
|---|---|
|
Olatunji Alese, MD
|
Has no relevant financial relationships
|
|
Pamela Blair Allen, MD, MSc
|
|
|
Kenneth C. Anderson, MD
|
Consultant/Advisor/Speaker: AstraZeneca, Johnson and Johnson, Pfizer Board of Directors: C4 Therapeutics, Starton, Window, Dynamic Cell Therapies, Predicta
|
|
Cletus Arciero, MD, FACS
|
Has no relevant financial relationships
|
|
Fatemeh Ardeshir, MD, MSc
|
Has no relevant financial relationships
|
|
Martha Arellano, MD
|
Consultant/Advisor/Speaker: SYNDAX Pharmaceuticals
|
|
James O. Armitage, MD
|
Consultant/Advisor/Speaker: Syncromune, Cardiff Oncology
|
|
Michael B. Atkins, MD
|
Consultant/Advisor/Speaker: AbbVie, AstraZeneca, BeiGene, Boehringer-Ingelheim Researcher: Agenus, BMS, Merck Board of Directors: Werewolf Pharma Individual publicly traded stocks and stock options: Pyxis Oncology
|
|
Abraham Attah, MD
|
Has no relevant financial relationships
|
|
James Bates, MD
| |
|
Jacob E. Berchuck, MD
|
Consultant/Advisor/Speaker: Guardant Health, Precede Biosciences, Tracer Biotechnologies, Genome Medical Researcher: Precede Biosciences Royalties or Patent Beneficiary: Precede Biosciences
|
|
Manali Bhave, MD
|
Consultant/Advisor/Speaker: Astrazeneca, Daiichi Sankyo, Eli Lilly, Gilead
|
|
Mehmet Asim Bilen, MD
|
Institutional Grant: Merck, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, Pfizer, Xencor
|
|
Kristie Blum, MD
|
|
|
William G. Blum, MD
|
|
|
Jacqueline Brown, MD
|
Consultant/Advisor/Speaker: Gilead Researcher: Duality Bio, Medicenna, Pliant Therapeutics
|
|
Jennifer Carlisle, MD
|
Consultant/Advisor/Speaker: Amgen, AstraZeneca, Novocure Institutional Research Funding: BlackDiamond, Chipscreen, Daiichi Sankyo, Genentech
|
|
Bradley Carthon, MD, PhD
|
Has no relevant financial relationships
|
|
Andres Chang, MD, PhD
|
Consultant/Advisor/Speaker: AbbVie, AstraZeneca
|
|
Jordan Ciuro, MD
|
Has no relevant financial relationships
|
|
Jonathon B. Cohen, MD, MS
|
Consultant/Advisor/Speaker: ADC Therapeutics, AstraZeneca, BeiGene, Janssen Reseacher: AstraZeneca, BeiGene, BMS, Genentech, Lilly, Novartis, Nurix, Takeda
|
|
Laura E. Donovan, MD
|
|
|
Anthony B. El-Khoueiry
|
|
|
Oluwadunni E. Emiloju, MBBS, MS
|
Individual publicly traded stocks and stock options: Telix
|
|
Frederick Flynt
|
|
|
David A. Frank, MD, PhD, FACP
|
|
|
Shipra Gandhi, MD
|
Consultant/Advisor/Speaker: AstraZeneca
|
|
Olumide Gbolahan, MBBS, MSc
|
Consultant/Advisor/Speaker: AstraZeneca Research Funding: AstraZeneca, Astellas Pharma, Jazz Pharmaceuticals, J&J, RLY Therapeutics, Roche, SeaGen Advisory Board: AstraZeneca
|
|
Daniel M. Halperin, MD
|
Consultant/Advisor/Speaker: Boeringer-Ingelheim, Exelixis, Lantheus, Novartis, Sanofi, Wren Laboratories
|
|
Lindsay Hannan, MD, MSc
|
Has no relevant financial relationships
|
|
Michael Hochman, MD
|
Has no relevant financial relationships
|
|
Craig C. Hofmeister, MD, MPH
|
|
|
Anthony Hunter, MD
|
Consultant/Advisor/Speaker: PharmaEssentia, Sobi Researcher: Ascentage Pharma, Cogent Biosciences, Incyte, Novartis, PharmaEssentia, Shenzen TargetRx, Syntrix Biosystems
|
|
Neil M. Iyengar, MD
|
Consultant/Advisor/Speaker: Arvinas, AstraZeneca, BD Life Sciences, Daichii-Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, SynDevRx
|
|
Ashesh Jani, MD, MSEE, FASTRO
|
Has no relevant financial relationships
|
|
Nisha Joseph, MD
|
Consultant/Advisor/Speaker: BMS, GSK
|
|
Kevin Kalinsky, MD, MS
|
|
|
Hagop Kantarjian, MD
|
Has no relevant financial relationships
|
|
Jonathan Kaufman, MD
|
Consultant/Advisor/Speaker: Ascentage, BMS, Sanofi, Sebia
|
|
Fadlo Khuri, MD
|
Has no relevant financial relationships
|
|
Jean Koff, MD, MS
|
Consultant/Advisor/Speaker: AbbVie, BeOne, Pierre Fabre
|
|
Amelia A. Langston, MD
|
Research Support (trial): Acepodia, BMS, Indapta, Miltenyi DSMB for a trial: Moderna
|
|
Ticiana Leal, MD
|
Consultant/Advisor/Speaker: Jazz, Genentech, BI, AstraZeneca, Novocure, Catalyst, OncoC4, J&J
|
|
Mary Jo Lechowicz, MD
|
DSMB: Solgenix
|
|
Sagar Lonial, MD, FACP
|
|
|
Michael Lowe, MD, MA
|
Has no relevant financial relationships
|
|
Beryl Manning-Geist, MD
|
Consultant/Advisor/Speaker: Caris
|
|
Steve McCune
|
|
|
Kristy McDonald, MD
|
|
|
Jane Lowe Meisel, MD
|
Consultant/Advisor/Speaker: AstraZeneca, Olema, Pfizer, Sermonix Researcher: AstraZeneca, Olema, Sermonix
|
|
Ruoyu Miao, MD
|
Has no relevant financial relationships
|
|
Susan Modesitt, MD, FACOG, FACS
|
Consultant/Advisor/Speaker: Targeted Oncology
|
|
Duane Moores, MD
|
|
|
Vikram M. Narayan, MD
|
Consultant/Advisor/Speaker: Valar Labs
|
|
Edjah K. Nduom, MD, FAANS
|
Has no relevant financial relationships
|
|
Ajay K. Nooka, MD, MPH, FACP
|
Consultant/Advisor/Speaker: Adaptive Biotechnologies, Astrazeneca, Cellectar Biosciences, GlaxoSmithKline, Janssen, K36 Therapeutics, KITE therapeutics, ONK therapeutics, OPNA, Pfizer, Sanofi, Sebia
|
|
Susan M. O’Brien, MD
|
Consultant/Advisor/Speaker: AbbVie, AstraZeneca, Autolus, Beigene, Ltd., Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Loxo Oncology, Inc., Merck, Pfizer, Pharmacyclics Research: Alliance, Caribou Biosciences, Inc., Nurix Therapeutics, Inc., Regeneron Scientific Advisory Board: Somitomo
|
|
Sope Olugbile, MD
|
|
|
Byram Ozer, MD, PhD
|
Has no relevant financial relationships
|
|
Ravi B. Parikh, MD, MPP, FACP
|
Consultant/Advisor/Speaker: Main Street Health, Mendei ai, Onc ai, Optinosis, Thyme Care
|
|
Mihir R. Patel, MD
|
|
|
Suresh Ramalingam, MD, FASCO
|
|
|
Nabil Saba, MD, FACP
|
Consultant/Advisor/Speaker: Exelixis, EMD Serono, Merck
|
|
Elizabeth Sakach, MD
|
Has no relevant financial relationships
|
|
Jennifer M. Scalici, MD
|
Has no relevant financial relationships
|
|
Charles Staley, MD
|
Has no relevant financial relationships
|
|
Kristen Starbuck, MD
|
|
|
Conor E. Steuer, MD
|
Consultant/Advisor/Speaker: Daiichi Sankyo
|
|
Patrick Sullivan, MD, FACS
|
Has no relevant financial relationships
|
|
Bradley Sumrall
|
|
|
Sibo Tian, MD
|
Consultant/Advisor/Speaker: Bio Ascend, Emory
|
|
Mylin Torres, MD
|
Educational Lectures: Varian
|
|
Eric Turner
|
|
|
Colin Vale, MD
|
Has no relevant financial relationships
|
|
Melinda Yushak, MD, MPH
|
Has no relevant financial relationships
|
|
Mosun Oyenuga, MD, MPH
|
Has no relevant financial relationships
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit Information Coming Soon!